Award
National Cancer Institute 5R01CA279993-03
Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancer
Recipient
Johns Hopkins University
Award Amount
$574,881.00
Ceiling
$574,881.00
Awarded
March 05, 2026
Identifier
5R01CA279993-03
This award funds research to identify molecular features that promote sensitivity to LSD1 inhibitors in castration-resistant prostate cancer, focusing on neuroendocrine prostate cancer to guide future clinical trials.
Description
Prostate cancer (PCa) remains an incurable disease once progression to the metastatic castration-resistant (mCRPC) state occurs; killing >30,000 U.S. men/yr. Herein, we put forward an innovative strategy to selectively exploit vulnerabilities in neuroendocrine prostate cancer (NEPC), a highly aggressive variant of mCRPC, using an orally-bioavailable and highly specific LSD1 inhibitor, bomedemstat, in clinical development for unrelated indications. Genome-scale analyses will provide mechanistic understanding of the genetic and epigenetic features underlying the subtype specificity to LSD1 inhibition, guiding patient selection in future biomarker-driven clinical trials.